Skip to content
10-Q

Quarterly Report

Celldex Therapeutics, Inc. CLDX

0001410578-24-001219

← back to feed
Filed
Aug 8, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2024 · Jul 31, 2024 66.29M sh
Cash And Equivalents Q2 2024 · Jun 30, 2024 $42.74M
Cash And Equivalents Q2 2024 · Dec 31, 2023 $34.81M
Current Liabilities Q2 2024 · Jun 30, 2024 $27.66M
Current Liabilities Q2 2024 · Dec 31, 2023 $31.13M
Total Liabilities Q2 2024 · Jun 30, 2024 $31.93M
Total Liabilities Q2 2024 · Dec 31, 2023 $36.46M
Current Assets Q2 2024 · Jun 30, 2024 $811.98M
Current Assets Q2 2024 · Dec 31, 2023 $431.69M
Total Assets Q2 2024 · Jun 30, 2024 $845.59M
Total Assets Q2 2024 · Dec 31, 2023 $465.63M
Shares Diluted Q2 2024 · Jun 30, 2023 47.25K sh
Shares Diluted Q2 2024 · Jun 30, 2023 47.23K sh
Capex Q2 2024 · Jun 30, 2023 $995K
Operating Cash Flow Q2 2024 · Jun 30, 2023 −$55.77M
Stockholders Equity Q2 2024 · Jun 30, 2023 $277.54M
Stockholders Equity Q2 2024 · Mar 31, 2023 $302.74M
Stockholders Equity Q2 2024 · Dec 31, 2022 $326.2M
Eps Diluted Q2 2024 · Jun 30, 2023 −$0.65
Eps Diluted Q2 2024 · Jun 30, 2023 −$1.27
Eps Basic Q2 2024 · Jun 30, 2023 −$0.65
Eps Basic Q2 2024 · Jun 30, 2023 −$1.27
Sga Expense Q2 2024 · Jun 30, 2023 $7.22M
Sga Expense Q2 2024 · Jun 30, 2023 $13.86M
Rd Expense Q2 2024 · Jun 30, 2023 $26.25M
Rd Expense Q2 2024 · Jun 30, 2023 $53.05M
Operating Income Q2 2024 · Jun 30, 2023 −$33.21M
Operating Income Q2 2024 · Jun 30, 2023 −$65.68M
Revenue Q2 2024 · Jun 30, 2023 $268K
Revenue Q2 2024 · Jun 30, 2023 $1.23M